Cancer Immunology, Immunotherapy

, Volume 52, Issue 8, pp 506–512 | Cite as

Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications

  • Young Kee Shin
  • Yoon La Choi
  • Eun Young Choi
  • Min Kyung Kim
  • Myeong-Cherl Kook
  • Junho Chung
  • Yang-Kyu Choi
  • Heung Sik Kim
  • Hyung Geun Song
  • Seong Hoe Park
Original Article


We have previously reported the identification of a unique thymocyte-specific surface molecule, JL1, which was detected using the monoclonal antibody (mAb), anti-JL1. Interestingly, JL1 was shown to be expressed in most leukemias, irrespective of their immunophenotype, and subpopulations of normal bone marrow (BM) mononuclear cells (MNCs). Here we investigated the potential usefulness of the anti-JL1 mAb as a therapeutic tool for leukemia. We demonstrated that the proliferation of cultured human leukemia cells was dramatically inhibited in vitro by anti-JL1 mAb conjugated with the polypeptide toxin, gelonin, but not by gelonin alone. We then systematically investigated the reactivity of the anti-JL1 mAb against normal human tissues to evaluate possible side effects along with various hematopoietic and nonhematopoietic tumor cell lines. All of 33 types of normal tissues except thymus and subpopulation of BM MNCs were clearly devoid of JL1 expression. Among tumor cell lines, all the nonhematopoietic cell lines tested were negative for JL1 expression, while some hematopoietic cell lines contained JL1 antigen. Collectively, the results showed the cytotoxic effects of anti-JL1-based immunotoxin against JL1-positive leukemic cells, sparing most normal tissues other than thymocytes and some BM MNCs. Therefore, we strongly suggest that gelonin-conjugated anti-JL1 mAb immunotoxin could be developed as a potential immunotherapeutic agent in the treatment of various types of JL1-positive acute leukemias.


JL1 Leukemia Immunotoxin Gelonin 


  1. 1.
    Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624PubMedGoogle Scholar
  2. 2.
    Appelbaum FR (1999) Antibody-targeted therapy for myeloid leukemia. Semin Hematol 36 [Suppl 6]: 2Google Scholar
  3. 3.
    Barbieri L, Battelli MG, Stirpe F (1993) Ribosome-inactivating proteins from plants. Biochim Biophys Acta 1154:237PubMedGoogle Scholar
  4. 4.
    Bernstein ID (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 14:474CrossRefPubMedGoogle Scholar
  5. 5.
    Caron PC, Scheinberg DA (1994) Immunotherapy for acute leukemias. Curr Opin Oncol 6:14PubMedGoogle Scholar
  6. 6.
    Caron PC, Dumont L, Scheinberg DA (1998) Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 4:1421PubMedGoogle Scholar
  7. 7.
    Chung JK, So Y, Hong MK, Choi SR, Jeong JM, Lee DS, Lee MC, Koh CS, Choi EY, Park SH (1997) In vitro and in vivo properties of murine monoclonal antibody for a novel immature thymocyte-differentiated antigen, JL1. Nucl Med Biol 24:433Google Scholar
  8. 8.
    Dillman RO (1994) Antibodies as cytotoxic therapy. J Clin Oncol 12:1497PubMedGoogle Scholar
  9. 9.
    Eaves CJ (1995) Assays of hematopoietic progenitor cells. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds) Williams hematology, 5th edn. McGraw-Hill, New York. p L22Google Scholar
  10. 10.
    Gagnon P (1996) Protein A affinity purification: In: Purification tools for monoclonal antibodies, 1st edn. Validated Biosystems, Tucson, p 158Google Scholar
  11. 11.
    Hardy RR (1986) Purification and coupling of fluorescent proteins for use in flow cytometry. In: Weir DM, Herzenberg LA, Blackwell CC, Herzenberg LA (eds) Handbook of experimental immunology, 1st edn. Blackwell Scientific, Oxford, p 31Google Scholar
  12. 12.
    Harris WJ, Cunningham C (1995) Clinical studies with murine and chimeric monoclonal antibodies. In: Antibody therapeutics, 1st edn. R.G. Landes, Austin, p 39Google Scholar
  13. 13.
    Hermanson GT (1996) Tags and probes. In: Bioconjugate techniques, 1st edn. Academic Press, San Diego, p 297Google Scholar
  14. 14.
    Hertler AA, Frankel AE (1989) Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 7:1932PubMedGoogle Scholar
  15. 15.
    Maloney DG (1999) Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches. Curr Opin Hematol 6:222CrossRefPubMedGoogle Scholar
  16. 16.
    Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, Martin PJ, Mitchell D, Press OW, Storb R, Bernstein ID (1999) Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94:1237PubMedGoogle Scholar
  17. 17.
    McGraw KJ, Rosenblum MG, Cheung L, Scheinberg DA (1994) Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol Immunother 39:367PubMedGoogle Scholar
  18. 18.
    Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567PubMedGoogle Scholar
  19. 19.
    Park SH, Bae YM, Kwon HJ, Kim TJ, Kim J, Lee SJ, Lee SK (1993) JL1, a novel differentiation antigen of human cortical thymocyte. J Exp Med 178:1447PubMedGoogle Scholar
  20. 20.
    Park WS, Bae YM, Chung DH, Kim TJ, Choi EY, Chung JK, Lee MC, Park SY, Park MH, Park SH (1998) A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias. Leukemia 12:1583PubMedGoogle Scholar
  21. 21.
    Sahin U, Tureci O, Pfreundschuh M (1997) Serological identification of human tumor antigens. Curr Opin Immunol 9:709PubMedGoogle Scholar
  22. 22.
    Scott AM, Welt S (1997) Antibody-based immunological therapies. Curr Opin Immunol 9:717PubMedGoogle Scholar
  23. 23.
    Shin YK, Choi EY, Kim SH, Chung J, Chung DH, Park WS, Jung KC, Kim HS, Park S, Kim HJ, Park MH, Min CK, Kim CC, Park SH. (2001) Expression of leukemia-associated antigen, JL1, in bone marrow and thymus. Am J Pathol 158:1473PubMedGoogle Scholar
  24. 24.
    Sivam G, Pearson JW, Bohn W, Oldham RK, Sadoff JC, Morgan AC Jr (1987) Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates. Cancer Res 47:3169PubMedGoogle Scholar
  25. 25.
    Stirpe F, Olsnes S, Pihl A (1980) Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 255:6947PubMedGoogle Scholar
  26. 26.
    Suh W, Chung JK, Park SH, Kim SW (2001) Anti-JL1 antibody-conjugated poly(L-lysine) for targeted gene delivery to leukemia T cells. J Controlled Release 72:171CrossRefGoogle Scholar
  27. 27.
    Sutherland HJ, Eaves AC, Eaves CJ (1991) Quantitative assays for human hematopoietic progenitor cells. In: Gee AP (ed) Bone marrow processing and purging: a practical guide, 1st edn. CRC Press, Boca Raton, p 155Google Scholar
  28. 28.
    Testa NG, Molineux G (1993) Haemopoiesis: a practical approach. Oxford University Press, New YorkGoogle Scholar
  29. 29.
    Vitetta ES (1990) Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS. J Clin Immunol 10 [6 Suppl]:15SGoogle Scholar
  30. 30.
    Vitetta ES, Uhr JW (1994) Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res 54:5302Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Young Kee Shin
    • 1
    • 8
  • Yoon La Choi
    • 1
  • Eun Young Choi
    • 1
  • Min Kyung Kim
    • 2
  • Myeong-Cherl Kook
    • 1
  • Junho Chung
    • 3
    • 4
  • Yang-Kyu Choi
    • 5
  • Heung Sik Kim
    • 6
  • Hyung Geun Song
    • 7
  • Seong Hoe Park
    • 1
  1. 1.Department of PathologySeoul National University College of MedicineSeoulKorea
  2. 2.Department of Pathology, Ilsan Paik HospitalInje University College of MedicineIlsanKorea
  3. 3.Department of Biochemistry and Molecular Biology, Cancer Research InstituteSeoul National University College of MedicineSeoulKorea
  4. 4.National Cancer CenterGoyangKorea
  5. 5.Genetic Resources CenterKorea Research Institute of Bioscience and BiotechnologyDaejeonKorea
  6. 6.Department of PediatricsKeimyung University College of MedicineTaeguKorea
  7. 7.Department of PathologyChungbuk National University College of MedicineChungjuKorea
  8. 8.DiNonA Inc.SeoulKorea

Personalised recommendations